Glenmark Pharmaceuticals announced that it has agreed to a licensing deal giving Grandpharma exclusive rights to commercialize Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray in China.
The company recently announced that Yuhan had acquired South Korean rights to Ryaltris in South Korea. In July 2018, Glenmark said that it had reached an agreement with Seqirus for commercialization rights in Australia and New Zealand.
In the US, Glenmark submitted an NDA for Ryaltris in May 2018, and the FDA has set a PDUFA date of March 21, 2019 for completion of its review.
Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said, “We are happy to partner with Grandpharma in China as its product portfolio complements well with Ryaltris and this partnership gives us an opportunity to tap into one of the largest pharmaceutical markets in the world. This step is aligned with our vision to make Ryaltris the first global brand of Glenmark through launches in multiple markets across the globe.”
Read the Glenmark Pharmaceuticals press release.
